Interleukin-8 in the pathogenesis of primary central nervous system lymphoma in association with HIV infection

Figures & data

Figure 1. Expression of EBV genome and HIV mRNA. EBV transformation of LCL_HIV (Is, Sh, Ku, Ni) and LCL_N (Ki, Ma, Hi, Na) was confirmed by DNA PCR (A). The amplified EBV band was 142 bp. HIV infection was determined by RT-PCR (B). The expected HIV band was 134 bp; however, no band was observed.

Figure 2. Expression of adhesion molecules in LCLs by FACS. (A) Expressions of CD11a, CD11b, CD18, CD50, and CD54 were determined by FACS. The expression of CD18 by LCL_HIV was significantly greater than that by LCL_N. (B) Expressions of CD18 by LCL_HIV and LCL_N at several culture stages. The expression of CD18 in LCL_HIV (Is, Sh, Ku, Ni) was significantly greater than that in LCL_N (Ki, Ma, Hi, Na) by FACS at 0 hour (*P = 0.0102), 24 hours (**P = 0.0320), and 48 hours (***P = 0.0291).

Figure 3. Effects of simvastatin or AZT on proliferation of LCLs. Proliferation curve of LCL_HIV (A) or LCL_N (B) incubated with or without simvastatin. Effects of AZT on cell growth of LCL_HIV (C) or LCL_N (D).

Figure 4. Effects of simvastatin or AZT on CD18 expression of LCL_HIV or LCL_N. (A) Expression of CD18 by LCL_HIV was decreased significantly with simvastatin (*P = 0.0208) or AZT (**P = 0.0113). (B) Simvastatin induced downregulation of CD18 in LCL_N (*P = 0.0015), but AZT did not induce downregulation (**P = 0.0887).

Figure 5. Expression of CD54 and CD18 by ISO-HAS. Expressions of adhesion molecules in ISO-HAS by FACS. ISO-HAS mostly expressed ICAM-1 (CD54, 99.59%). No expression of LFA-1 (CD11a/CD18, 1.82%/1.39%) was detected.

Figure 6. Inhibition of binding between LCLs and ISO-HAS by simvastatin or AZT. (A) The binding rates of LCL_HIV and ISO-HAS without reagents were 97–99%. Binding rates were significantly decreased by simvastatin (0.5 µM final conc.) (*P < 0.0001) or AZT (8.0 µM final conc.) (**P < 0.0001). (B) The binding rates between ISO-HAS and LCL_N were 30–40% in spontaneous culture. Simvastatin (0.5 µM final conc.) (*P < 0.0001) or AZT (8.0 µM final conc.) induced significantly decreased binding (**P < 0.0001).

Figure 7. Effects of IL-8 on CD18 expression of LCL_HIV or LCL_N. Expression of CD18 by LCL_HIV (A) or LCL_N (B) increased with IL-8 (100 ng/ml final conc.) (LCL_HIV, *P = 0.0333; LCL_N, *P = 0.0073). (C) IL-8 level in culture supernatant from LCL_HIV was higher than that in supernatant from LCL_N (*P = 0.0171).

Figure 8. Effects of IL-8 on cell binding between LCL_N and ISO-HAS. The binding rate of LCL_N and ISO-HAS was augmented significantly when cultured with IL-8 (100 ng/ml final conc.) (*P = 0.0006).